Cancer Research Articles

Physicians and senior leaders of Florida Cancer Specialists & Research Institute (FCS) will be participating in the 2022 Community Oncology Conference hosted by the Community Oncology Alliance (COA) this week in Kissimmee, Florida.

Florida Cancer Specialists & Research Institute (FCS) is pleased to welcome Ken Sturtz, MBA, MHA to its executive leadership team as Chief Information Officer. He will oversee all information technology operations and drive digital innovation company-wide.

Three Florida Cancer Specialists & Research Institute (FCS) physicians presented clinical research findings at the American Society of Clinical Oncology (ASCO®) 2022 Genitourinary Cancers Symposium held February 17 – 19 in San Francisco, CA.

Medical oncologists Lucio  N. Gordan, MD and Ivor Percent, MD, members of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), are co-authors for a study that examined the safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) administered primarily in community-based settings.

Lime Connect (Lime) is pleased to announce that Nathan H. Walcker, Chief Executive Officer of Florida Cancer Specialists & Research Institute, has joined the not for profit organization as a member of its global board of directors.

Dr. Phelan identified the chromosome variant now known as Phelan-McDermid Syndrome

FCS announced the newest addition to its senior management team. Joshua Eaves joined FCS as Senior Vice President Corporate Development.

Hodgkin lymphoma, named after Dr. Thomas Hodgkin, is a cancer that affects the lymphatic system which makes up part of the body’s immune system. Specifically, Hodgkin lymphoma occurs when the DNA changes in white blood cells called lymphocytes.